雄激素受体在人肾细胞癌中的表达与评价。

The expression and evaluation of androgen receptor in human renal cell carcinoma.

机构信息

Sex Hormone Research Center, Department of Urology, The First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, China; George H. Whipple Lab for Cancer Research, Departments of Pathology and Urology, Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY.

出版信息

Urology. 2014 Feb;83(2):510.e19-24. doi: 10.1016/j.urology.2013.10.022. Epub 2013 Dec 12.

DOI:10.1016/j.urology.2013.10.022

PMID:24332122

Abstract

OBJECTIVE

To investigate the expression of androgen receptor (AR) with clinical and pathologic features in patients with renal cell carcinoma (RCC) and to explore the function of AR using human RCC cells.

MATERIALS AND METHODS

The expression of AR was detected by immunohistochemistry in 44 adjacent normal kidney tissues of 120 RCC patients and also in 16 metastatic RCC patients with their respective primary and metastatic tissue samples. The expression of AR was examined by western blot in commonly used human RCC cell lines and normal kidney epithelial cells, and the luciferase assay was performed in those AR-positive RCC cells.

RESULTS

The expression rate of AR was higher in adjacent normal kidney (90.9%) than in RCC tissues (30.0%, P <.001), and it was negatively associated with pT stage and Fuhrman's grade. Specifically, there were 40.7% AR-positive cases in pT1 compared with 8.0% in pT3 (P = .013), and 50.0% of grade I cases were found to be AR positive compared with 12.9% in grade III (P = .008). AR expression was slightly higher in primary RCC tissues (12.5%) than their respective metastases (0%, P = .484). AR strongly expressed in CAKI-2 and OSRC-2 cells with little transactivation, which might indicate that AR in those 2 RCC cells has little function.

CONCLUSION

Our results suggest that any attempt to investigate the roles of AR in RCC progression might need to combine the detection of AR expression in tissue samples with examining its function to make a correct correlation between AR and RCC progression.

摘要

目的

研究雄激素受体（AR）在肾细胞癌（RCC）患者中的表达及其与临床病理特征的关系，并利用人 RCC 细胞探讨 AR 的功能。

材料与方法

采用免疫组织化学方法检测 120 例 RCC 患者的 44 例相邻正常肾组织和 16 例转移性 RCC 患者的相应原发和转移组织中 AR 的表达，并用 Western blot 检测 AR 在常用的人 RCC 细胞系和正常肾上皮细胞中的表达，并用 AR 阳性 RCC 细胞进行荧光素酶检测。

结果

AR 在相邻正常肾组织（90.9%）中的表达率高于 RCC 组织（30.0%），差异有统计学意义（P<0.001），且与 pT 分期和 Fuhrman 分级呈负相关。具体而言，pT1 组 AR 阳性率为 40.7%，pT3 组为 8.0%（P=0.013），I 级 AR 阳性率为 50.0%，III 级为 12.9%（P=0.008）。AR 在原发性 RCC 组织中的表达（12.5%）略高于其相应转移灶（0%），差异无统计学意义（P=0.484）。AR 在 CAKI-2 和 OSRC-2 细胞中表达较强，但转录活性较低，这可能表明这两种 RCC 细胞中的 AR 功能较弱。